Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | AR | P10275 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1932012 | 0.82 | ATM (0.45) | ATMNPSR1CYP1A2PRMT5POLB | |
| SCHEMBL24000186 | 0.78 | CHEK1 (0.44) | ATMNPSR1PRMT5LMNATSHR | |
| SCHEMBL25839255 | 0.78 | CHEK1 (0.44) | CYP1A2PRMT5LMNAPARP1ALDH1A1 | |
| SCHEMBL14826495 | 0.77 | ADORA2A (0.42) | ATMNPSR1CYP1A2PRMT5POLB | |
| SCHEMBL19153584 | 0.76 | PRMT5 (0.44) | ATMNPSR1CYP1A2PRMT5POLB | |
| SCHEMBL19153845 | 0.76 | PARP1 (0.45) | CYP1A2PRMT5KMT2AHIF1AAURKA | |
| SCHEMBL1032659 | 0.76 | PRMT5 (0.60) | ATMNPSR1PRMT5POLBAR | |
| SCHEMBL19153217 | 0.75 | PARP1 (0.49) | CYP1A2PRMT5TSHRAURKAPARP1 | |
| SCHEMBL23914628 | 0.75 | PRMT5 (0.46) | PRMT5LMNAAURKAAURKBALDH1A1 | |
| SCHEMBL15633163 | 0.75 | PARP1 (0.51) | CYP1A2PRMT5POLBTSHRPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113234024-A | Novel preparation method of olapari | 北京迈索化学技术有限公司 | 2021-08-10 | — | — | CN | claimed |
| EP-2298769-B1 | Xanthin derivatives, their production and utilisation as medicine | BOEHRINGER INGELHEIM PHARMA (DE) | 2013-10-30 | — | — | EP | claimed |
| US-20130165428-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-06-27 | — | — | US | claimed |
| US-20120252782-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG (DE) | 2012-10-04 | — | — | US | claimed |
| US-20120035158-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG (DE) | 2012-02-09 | — | — | US | claimed |
| US-20110144083-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-16 | — | — | US | claimed |
| US-20100173916-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-08 | — | — | US | claimed |
| EP-1757606-B1 | Xanthinderivatives for use as medical agents and the preparation thereof | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-05-06 | — | — | EP | claimed |
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | claimed |
| EP-1368349-B1 | XANTHINE DERIVATIVE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-02-14 | — | — | EP | claimed |
| US-20060205711-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-09-14 | — | — | US | claimed |
| EP-1423120-A4 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORP (US) | 2005-12-28 | — | — | EP | claimed |
| US-6924284-B2 | PARP inhibitors | ICOS CORPORATION (US) | 2005-08-02 | — | — | US | claimed |
| JP-2005501848-A | — | — | 2005-01-20 | — | — | JP | claimed |
| EP-1423120-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2004-06-02 | — | — | EP | claimed |
| US-20040087588-A1 | Parp inhibitors | ICOS CORPORATION | 2004-05-06 | — | — | US | claimed |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-04-22 | — | — | US | claimed |
| WO-2003015785-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2003-02-27 | — | — | WO | claimed |
| US-4207112-A | STORAGE STABILITY | FUJI PHOTO FILM CO., LTD. (JP) | 1980-06-10 | — | — | US | claimed |
| JP-5229946-A | — | — | None | — | — | JP | disclosed |
| US-12558354-B2 | Tumor necrosis factor alpha (TNF-alpha) small molecule inhibitor | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-02-24 | — | — | US | disclosed |
| US-12421222-B2 | Substituted quinazolines as HDAC6 inhibitors | AUGUSTINE THERAPEUTICS (BE) | 2025-09-23 | — | — | US | disclosed |
| US-20250145604-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-05-08 | — | — | US | disclosed |
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-02-13 | — | — | US | disclosed |
| EP-4452265-A2 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | Augustine Therapeutics (BE) | 2024-10-30 | — | — | EP | disclosed |
| CN-118591375-A | Compounds as HDAC6 inhibitors and uses thereof | 奥古斯汀治疗公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240226128-A1 | NOVEL COMPOUNDS WITH DUAL INHIBITION ACTIVITY AGAINST SARS-COV-2 CRITICAL ENZYMES RDRP, MPRO AND HUMAN TMPRSS2 | UNIVERSITY OF SHARJAH (AE) | 2024-07-11 | — | — | US | disclosed |
| WO-2024112120-A1 | DEGRADER INCLUDING NOVEL C-MET PROTEIN LIGAND AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | 주식회사 이노큐어테라퓨틱스 | 2024-05-30 | — | — | WO | disclosed |
| CN-117915903-A | Compounds for the treatment of neurodegenerative, degenerative and metabolic disorders and uses thereof | 佛罗里达大学研究基金会公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20240124466-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-18 | — | — | US | disclosed |
| US-20230295105-A1 | PIPERIDINEDIONE DERIVATIVES | INNOCURE THERAPEUTICS, INC. (KR) | 2023-09-21 | — | — | US | disclosed |
| US-20230295105-A1 | PIPERIDINEDIONE DERIVATIVES | INNOCURE THERAPEUTICS, INC. (KR) | 2023-09-21 | — | — | US | disclosed |
| CN-113549015-B | Preparation method and application of 4-substituted phthalazinone derivative | 安徽工业大学 | 2023-07-14 | — | — | CN | disclosed |
| WO-2023118507-A2 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2023-06-29 | — | — | WO | disclosed |
| EP-4116298-A1 | PIPERIDINEDIONE DERIVATIVE | Innocure Therapeutics, Inc. (KR) | 2023-01-11 | — | — | EP | disclosed |
| US-20230000861-A1 | TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) SMALL MOLECULE INHIBITOR | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2023-01-05 | — | — | US | disclosed |
| EP-2998288-B1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARM INC (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-4011877-A2 | METHOD OF TREATING ELEVATED PLASMA CHOLESTEROL | Institut de Cardiologie de Montréal (CA) | 2022-06-15 | — | — | EP | disclosed |
| EP-3666767-B1 | PHTHALAZINONE DERIVATIVES, METHOD FOR THEIR PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING THEM, AND THEIR USE | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-12-01 | — | — | EP | disclosed |
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| CN-113549015-A | Preparation method and application of 4-substituted phthalazinone derivative | 安徽工业大学 | 2021-10-26 | — | — | CN | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| CN-113234024-A | Novel preparation method of olapari | 北京迈索化学技术有限公司 | 2021-08-10 | — | — | CN | disclosed |
| CN-113234024-A | Novel preparation method of olapari | 北京迈索化学技术有限公司 | 2021-08-10 | — | — | CN | disclosed |
| US-11040952-B2 | Phthalazinone compound, method for preparation thereof, pharmaceutical composition thereof, and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2021-06-22 | — | — | US | disclosed |
| US-10961256-B2 | PRMT5 inhibitors | CTXT PTY LTD (AU) | 2021-03-30 | — | — | US | disclosed |
| US-10961256-B2 | PRMT5 inhibitors | CTXT PTY LTD (AU) | 2021-03-30 | — | — | US | disclosed |
| CN-107903416-B | Polyaryletherketone zwitter-ion exchange membrane containing phthalazinone structure and preparation method thereof | 大连理工大学 | 2021-01-19 | — | — | CN | disclosed |
| EP-3426647-B1 | TETRAHYDROISOQUINOLINES AS PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2020-11-18 | — | — | EP | disclosed |
| EP-3426640-B1 | PRMT5 INHIBITORS | CTXT PTY LTD (AU) | 2020-11-18 | — | — | EP | disclosed |
| EP-3426640-B1 | PRMT5 INHIBITORS | CTXT PTY LTD (AU) | 2020-11-18 | — | — | EP | disclosed |
| EP-3666767-A1 | PYRIDAZINONE COMPOUND, METHOD FOR PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2020-06-17 | — | — | EP | disclosed |
| US-20200181109-A1 | PHTHALAZINONE COMPOUND, METHOD FOR PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-06-11 | — | — | US | disclosed |
| CN-110869359-A | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | 加拉帕戈斯股份有限公司 | 2020-03-06 | — | — | CN | disclosed |
| US-20200060995-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2020-02-27 | — | — | US | disclosed |
| US-10550096-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | CTXT PTY LTD (AU) | 2020-02-04 | — | — | US | disclosed |
| EP-3426640-A1 | PRMT5 INHIBITORS | Ctxt Pty Ltd (AU) | 2019-01-16 | — | — | EP | disclosed |
| US-20180256517-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2018-09-13 | — | — | US | disclosed |
| US-20180093976-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180085327-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2018-03-29 | — | — | US | disclosed |
| US-9783529-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| WO-2017153518-A1 | PRMT5 INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153518-A1 | PRMT5 INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017106568-A1 | COMBINATION OF A JAK INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER | GILEAD SCIENCES, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-9682969-B2 | Phthalazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170158673-A1 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-08 | — | — | US | disclosed |
| US-20170158673-A1 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-08 | — | — | US | disclosed |
| US-9522905-B2 | Quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-20 | — | — | US | disclosed |
| US-20160361275-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160318847-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2016-11-03 | — | — | US | disclosed |
| US-9458145-B2 | Benzimidazole derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458082-B2 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9422225-B2 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| EP-2998288-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | Auspex Pharmaceuticals, Inc. (US) | 2016-03-23 | — | — | EP | disclosed |
| US-20150299176-A1 | PHTHALAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2015-10-22 | — | — | US | disclosed |
| EP-1954669-B1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS INC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-8987256-B2 | Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| CN-102083803-B | Oxocyclic substituted carboxylic acid derivatives and their use | BAYER IP GMBH | 2015-02-18 | — | — | CN | disclosed |
| US-8937178-B2 | Phthalazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB (US) | 2015-01-20 | — | — | US | disclosed |
| US-20150005300-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140336190-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140296339-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2014-10-02 | — | — | US | disclosed |
| US-20140274933-A1 | PHTHALAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-09-18 | — | — | US | disclosed |
| EP-2305250-B1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2014-03-26 | — | — | EP | disclosed |
| US-20140080835-A1 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-20 | — | — | US | disclosed |
| US-8629143-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20140010892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-01-09 | — | — | US | disclosed |
| US-20140010892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-01-09 | — | — | US | disclosed |
| EP-1648426-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2014-01-08 | — | — | EP | disclosed |
| US-8623872-B2 | Quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-07 | — | — | US | disclosed |
| US-20130165428-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-06-27 | — | — | US | disclosed |
| US-20120252782-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG (DE) | 2012-10-04 | — | — | US | disclosed |
| EP-2504317-A1 | POTASSIUM CHANNEL MODULATORS | Abbott Laboratories (US) | 2012-10-03 | — | — | EP | disclosed |
| US-20120237566-A1 | INHIBITING STOMACH-ACID RELEASE, REDUCING INFLAMMATION AND PREVENTING AND TREATING CANCER: COMPOSITIONS AND METHODS OF USE | Venture Isles, LLC (US) | 2012-09-20 | — | — | US | disclosed |
| US-8188103-B2 | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-29 | — | — | US | disclosed |
| EP-2268625-B1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF | Bayer Pharma AG (DE) | 2012-05-16 | — | — | EP | disclosed |
| US-8138226-B2 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | AUSPEX PHARMACEUTICALS (US) | 2012-03-20 | — | — | US | disclosed |
| US-20120035158-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG (DE) | 2012-02-09 | — | — | US | disclosed |
| US-20110224203-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-09-15 | — | — | US | disclosed |
| US-20110224203-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-09-15 | — | — | US | disclosed |
| EP-2354126-A1 | Heteroaryl sulfonamides and CCR2 | ChemoCentryx, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| US-7977477-B2 | Benzimidazole derivatives and their use as protein kinase inhibitors | ASTEX THERAPEUTICS, LIMITED (GB) | 2011-07-12 | — | — | US | disclosed |
| US-7977477-B2 | Benzimidazole derivatives and their use as protein kinase inhibitors | ASTEX THERAPEUTICS, LIMITED (GB) | 2011-07-12 | — | — | US | disclosed |
| US-20110144083-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-16 | — | — | US | disclosed |
| US-20110136914-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110130424-A1 | SUBSTITUTED PHENYLPIPERIDINES WITH SEROTONINERGIC ACTIVITY AND ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
| EP-2305250-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2011-04-06 | — | — | EP | disclosed |
| US-20110077245-A1 | SUBSTITUTED 2-ALKYL QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | VAN DER AA MARCEL JOZEF MARIA | 2011-03-31 | — | — | US | disclosed |
| EP-2081893-B1 | SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS INC (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIEGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| US-7875621-B2 | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-25 | — | — | US | disclosed |
| EP-2268625-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-01-05 | — | — | EP | disclosed |
| US-20100173916-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-08 | — | — | US | disclosed |
| US-20100137244-A1 | PREPARATION AND UTILITY OF HMG-COA REDUCTASE INHIBITORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20090312435-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009127338-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009123870-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-7598273-B2 | Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090215831-A1 | INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090209592-A1 | INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| EP-2081893-A2 | SUBSTITUTED INDOLES | Auspex Pharmaceuticals, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20090023765-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090018207-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20080312223-A1 | Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080312223-A1 | Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-7456317-B2 | Deuterated venlafaxine derivatives; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters; for intravenous administration; tablet/capsule form | AUSPEX PHARMACEUTICALS (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1954669-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | Auspex Pharmaceuticals Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1951643-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | Auspex Pharmaceuticals Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1948646-A2 | SUBSTITUTED PHENYLPIPERIDINES WITH SEROTONINERGIC ACTIVITY AND ENHANCED THERAPEUTIC PROPERTIES | Auspex Pharmaceuticals Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080176876-A1 | Poly(ADP-ribose)polymerase (PARP); ischemia, reperfusion injuries, neurological disorders, neuroprotectants, sensitizer for chemotherapy or radiotherapy, anticancer | JANSSEN PHARMACEUTICA, NV (BE) | 2008-07-24 | — | — | US | disclosed |
| EP-1934201-A1 | DEUTERATED INHIBITORS OF GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | Auspex Pharmaceuticals Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20080103189-A1 | PREPARATION AND UTILITY OF SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2008049116-A2 | SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| US-20080070915-A1 | Poly(ADP-ribose)polymerase (PARP); ischemia, reperfusion injuries, neurological disorders, neuroprotectants, sensitizer for chemotherapy or radiotherapy, anticancer | JANSSEN-CILAG (FR) | 2008-03-20 | — | — | US | disclosed |
| WO-2008008442-A1 | PREPARATION AND UTILITY OF HMG-COA REDUCTASE INHIBITORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070155820-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070149622-A1 | Deuterated venlafaxine derivatives formed by decyclization with formic acid; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2007064697-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007062119-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007058998-A2 | SUBSTITUTED PHENYLPIPERIDINES WITH SEROTONINERGIC ACTIVITY AND ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-7220858-B2 | Synthesis of hydrazine and chlorinated derivatives of bicyclic pyridazines | BARBEAU PHARMA, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20070112031-A1 | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| WO-2007041630-A1 | DEUTERATED INHIBITORS OF GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070082929-A1 | Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC. | 2007-04-12 | — | — | US | disclosed |
| US-20060205711-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-09-14 | — | — | US | disclosed |
| WO-2006070192-A1 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES THAT MODULATE THE ACIVITY OF CDK, GSK AND AURORA KYNASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006003147-A1 | PHTHALAZINE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-12 | — | — | WO | disclosed |
| EP-1423120-A4 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORP (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6924284-B2 | PARP inhibitors | ICOS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| US-20050137397-A1 | Synthesis of hydrazine derivatives of pyridazine | BIONICHE TEORANTA | 2005-06-23 | — | — | US | disclosed |
| WO-2005002552-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| EP-1423120-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20040087588-A1 | Parp inhibitors | ICOS CORPORATION | 2004-05-06 | — | — | US | disclosed |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-04-22 | — | — | US | disclosed |
| WO-2003015785-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-0971917-B1 | THIAZOLIDINEDIONE AND OXAZOLIDINEDIONE DERIVATIVES HAVING ANTIDIABETIC, HYPOLIPIDAEMIC AND ANTIHYPERTENSIVE PROPERTIES | REDDY RESEARCH FOUNDATION (IN) | 2002-02-06 | — | — | EP | disclosed |
| EP-0971917-A1 | THIAZOLIDINEDIONE AND OXAZOLIDINEDIONE DERIVATIVES HAVING ANTIDIABETIC, HYPOLIPIDAEMIC AND ANTIHYPERTENSIVE PROPERTIES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-01-19 | — | — | EP | disclosed |
| US-6011036-A | Heterocyclic compounds having antidiabetic hypolipidemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-01-04 | — | — | US | disclosed |
| WO-1998045292-A1 | THIAZOLIDINEDIONE AND OXAZOLIDINEDIONE DERIVATIVES HAVING ANTIDIABETIC, HYPOLIPIDAEMIC AND ANTIHYPERTENSIVE PROPERTIES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1998-10-15 | — | — | WO | disclosed |
| EP-0625978-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-30 | — | — | EP | disclosed |
| EP-0331314-B1 | Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate | PFIZER (US) | 1994-04-06 | — | — | EP | disclosed |
| JP-H05229946-A | ANTIULCER AGENT CONTAINING TRIAZOLOPHTHALAZINE DERIVATIVE | SAPPORO BREWERIES LTD | 1993-09-07 | — | — | JP | disclosed |
| WO-1993016073-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-19 | — | — | WO | disclosed |
| WO-1993013092-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | SARGES REINHARD (US) | 1993-07-08 | — | — | WO | disclosed |
| US-5114952-A | Side effect reduction | PFIZER INC. (US) | 1992-05-19 | — | — | US | disclosed |
| US-5011840-A | Imidazolidinedione derivatives in diabetes treatment | PFIZER INC. (US) | 1991-04-30 | — | — | US | disclosed |
| EP-0269355-B1 | IMIDAZOLIDINEDIONE DERIVATIVES | PFIZER INC. (US) | 1991-04-10 | — | — | EP | disclosed |
| US-4990509-A | Sulfonamide anti-arrhythmic agents | PFIZER INC. (US) | 1991-02-05 | — | — | US | disclosed |
| US-4940791-A | Process for the production of phthalazineacetic acid ester derivatives and a novel hydrazine containing intermediate | PFIZER INC. (US) | 1990-07-10 | — | — | US | disclosed |
| US-4904782-A | Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate | PFIZER INC. (US) | 1990-02-27 | — | — | US | disclosed |
| EP-0331314-A2 | Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate | PFIZER INC. (US) | 1989-09-06 | — | — | EP | disclosed |
| US-4863948-A | Isoindolinone sulfonamide anti-arrhythmic agents | PFIZER, INC. (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0269355-A1 | Imidazolidinedione derivatives | PFIZER INC. (US) | 1988-06-01 | — | — | EP | disclosed |
| EP-0242173-A1 | Antiarrhythmic agents | Pfizer Limited (GB) | 1987-10-21 | — | — | EP | disclosed |
| US-4237215-A | DECOMPOSING N-HALO COMPOUND IN PRESENCE OF ORGANIC SILVER SALT TO PRODUCE SILVER HALIDE | FUJI PHOTO FILM CO., LTD. (JP) | 1980-12-02 | — | — | US | disclosed |
| US-4207112-A | STORAGE STABILITY | FUJI PHOTO FILM CO., LTD. (JP) | 1980-06-10 | — | — | US | disclosed |
| US-4144072-A | CONTAINING A PHTHALAZINONE AND A PHTHALIMIDE | FUJI PHOTO FILM CO., LTD. (JP) | 1979-03-13 | — | — | US | disclosed |
| US-4125403-A | ORGANIC SILVER SALT, SILVER HALIDE, REDUCING AGENT, PHTHALAZINONE, AND A BENZOXAZINEDIONE OR QUINAZOLINEDIONE | FUJI PHOTO FILM CO., LTD. | 1978-11-14 | — | — | US | disclosed |
| US-4076534-A | Heat developable light-sensitive material | FUJI PHOTO FILM CO., LTD. (JA) | 1978-02-28 | — | — | US | disclosed |
| US-4076534-A | Heat developable light-sensitive material | FUJI PHOTO FILM CO., LTD. (JA) | 1978-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224203-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | CDK1, CCNI, CDK2 | ATM 468/4885NPSR1 4870/4885CYP1A2 2162/4885 |
| US-20200181109-A1 | PHTHALAZINONE COMPOUND, METHOD FOR PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | POLRMT, POLN, HCCS | ATM 4711/4885NPSR1 3538/4885CYP1A2 1001/4885 |
| US-20090312435-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | ATM 2239/4885NPSR1 49/4885CYP1A2 1930/4885 |
| US-20110144083-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | DPP4, DPP3, DPP7 | ATM 4376/4885NPSR1 474/4885CYP1A2 203/4885 |
| US-20110136914-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | ATM 1969/4885NPSR1 44/4885CYP1A2 1159/4885 |
| US-20180256517-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | SLC6A4, HTR4, GPR34 | ATM 2239/4885NPSR1 49/4885CYP1A2 1930/4885 |
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | HDAC6, HDAC9, HDAC1 | ATM 1878/4885NPSR1 1214/4885CYP1A2 3088/4885 |
| US-20200060995-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | SLC6A4, HTR4, GPR34 | ATM 2239/4885NPSR1 49/4885CYP1A2 1930/4885 |
| US-20070155820-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | ATM 1969/4885NPSR1 44/4885CYP1A2 1159/4885 |
| US-20090209592-A1 | INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | ATP4A, ATP6V1G1, ATP6V1E1 | ATM 4662/4885NPSR1 2497/4885CYP1A2 1768/4885 |
| US-20040087588-A1 | Parp inhibitors | PARP1, PARP2, PARP11 | ATM 414/4885NPSR1 2354/4885CYP1A2 567/4885 |
| US-20080176876-A1 | Poly(ADP-ribose)polymerase (PARP); ischemia, reperfusion injuries, neurological disorders, neuroprotectants, sensitizer for chemotherapy or radiotherapy, anticancer | PARP1, PARP2, PARP3 | ATM 30/4885NPSR1 1730/4885CYP1A2 3703/4885 |
| US-20100137244-A1 | PREPARATION AND UTILITY OF HMG-COA REDUCTASE INHIBITORS | HMGCR, COASY, ECHS1 | ATM 2228/4885NPSR1 1977/4885CYP1A2 611/4885 |
| US-20080103189-A1 | PREPARATION AND UTILITY OF SUBSTITUTED INDOLES | IDO1, TPH1, IDO2 | ATM 3309/4885NPSR1 97/4885CYP1A2 17/4885 |
| US-20070082929-A1 | Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties | ATP4A, ATP6V1G1, ATP6V1E1 | ATM 4662/4885NPSR1 2497/4885CYP1A2 1768/4885 |
| US-20090018207-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | ATM 2239/4885NPSR1 49/4885CYP1A2 1930/4885 |
| US-20130165428-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP3, DPP7 | ATM 4376/4885NPSR1 474/4885CYP1A2 203/4885 |
| US-20150005300-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, PNPO | ATM 1872/4885NPSR1 3769/4885CYP1A2 693/4885 |
| US-12558354-B2 | Tumor necrosis factor alpha (TNF-alpha) small molecule inhibitor | TNF, TNFRSF1A, TNFRSF9 | ATM 2609/4885NPSR1 4188/4885CYP1A2 2663/4885 |
| US-20160361275-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | ATM 2239/4885NPSR1 49/4885CYP1A2 1930/4885 |
| US-20100173916-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | DPP4, DPP3, DPP7 | ATM 4376/4885NPSR1 474/4885CYP1A2 203/4885 |
| US-20060205711-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | ATM 4376/4885NPSR1 474/4885CYP1A2 203/4885 |
| US-20250145604-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | HDAC6, HDAC9, HDAC1 | ATM 1878/4885NPSR1 1214/4885CYP1A2 3088/4885 |
| US-20140010892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | CDK1, CCNI, CDK2 | ATM 468/4885NPSR1 4870/4885CYP1A2 2162/4885 |
| US-20070149622-A1 | Deuterated venlafaxine derivatives formed by decyclization with formic acid; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters | SLC6A4, HTR4, OPRK1 | ATM 2535/4885NPSR1 64/4885CYP1A2 1156/4885 |
| US-20230295105-A1 | PIPERIDINEDIONE DERIVATIVES | CRBN, CUL1, PSMB10 | ATM 2998/4885NPSR1 3530/4885CYP1A2 4804/4885 |
| US-20120035158-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | DPP4, DPP3, DPP7 | ATM 4376/4885NPSR1 474/4885CYP1A2 203/4885 |
| US-20240226128-A1 | NOVEL COMPOUNDS WITH DUAL INHIBITION ACTIVITY AGAINST SARS-COV-2 CRITICAL ENZYMES RDRP, MPRO AND HUMAN TMPRSS2 | TMPRSS2, ACE2, TMPRSS4 | ATM 1546/4885NPSR1 2541/4885CYP1A2 629/4885 |
| US-20180093976-A1 | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, PNPO | ATM 1872/4885NPSR1 3769/4885CYP1A2 693/4885 |
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | OTC, PC, HCAR2 | ATM 2812/4885NPSR1 2623/4885CYP1A2 119/4885 |
| US-20120252782-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | DPP4, DPP3, DPP7 | ATM 4376/4885NPSR1 474/4885CYP1A2 203/4885 |
| US-20050137397-A1 | Synthesis of hydrazine derivatives of pyridazine | DHPS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HPD | ATM 3966/4885NPSR1 1845/4885CYP1A2 174/4885 |
| US-20160318847-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | ATM 2239/4885NPSR1 49/4885CYP1A2 1930/4885 |
| US-20080312223-A1 | Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases | CDK1, CDK8, CDK2 | ATM 330/4885NPSR1 3752/4885CYP1A2 1607/4885 |
| US-20140080835-A1 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP3, PARP2 | ATM 83/4885NPSR1 3059/4885CYP1A2 705/4885 |
| US-20150299176-A1 | PHTHALAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, PKD2 | ATM 4044/4885NPSR1 3900/4885CYP1A2 2781/4885 |
| US-20090215831-A1 | INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | ATP4A, ATP6V1G1, ATP6V1E1 | ATM 4662/4885NPSR1 2497/4885CYP1A2 1768/4885 |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | CDK1, AURKA, CDK2 | ATM 676/4885NPSR1 4868/4885CYP1A2 2318/4885 |
| US-10961256-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | ATM 1361/4885NPSR1 2611/4885CYP1A2 3640/4885 |
| US-20120237566-A1 | INHIBITING STOMACH-ACID RELEASE, REDUCING INFLAMMATION AND PREVENTING AND TREATING CANCER: COMPOSITIONS AND METHODS OF USE | SLC30A5, TRPA1, SLC30A7 | ATM 3879/4885NPSR1 1855/4885CYP1A2 2182/4885 |
| US-10550096-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | ATM 1721/4885NPSR1 2503/4885CYP1A2 2982/4885 |
| US-20090023765-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | ATM 2239/4885NPSR1 49/4885CYP1A2 1930/4885 |
| US-20240124466-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | SNCA, NLN, HTT | ATM 2767/4885NPSR1 1286/4885CYP1A2 1103/4885 |
| US-12421222-B2 | Substituted quinazolines as HDAC6 inhibitors | HDAC6, HDAC9, HDAC1 | ATM 1639/4885NPSR1 1247/4885CYP1A2 2671/4885 |
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNQ3 | ATM 3548/4885NPSR1 505/4885CYP1A2 1589/4885 |
| US-20080070915-A1 | Poly(ADP-ribose)polymerase (PARP); ischemia, reperfusion injuries, neurological disorders, neuroprotectants, sensitizer for chemotherapy or radiotherapy, anticancer | PARP1, PARP2, PARP11 | ATM 35/4885NPSR1 1591/4885CYP1A2 3484/4885 |
| US-20230000861-A1 | TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) SMALL MOLECULE INHIBITOR | TNF, TNFRSF1A, TNFRSF9 | ATM 1849/4885NPSR1 4802/4885CYP1A2 3131/4885 |
| US-20070112031-A1 | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties | SLC6A4, HTR4, HTR5A | ATM 2051/4885NPSR1 104/4885CYP1A2 1906/4885 |
| US-20170158673-A1 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP3, PARP2 | ATM 83/4885NPSR1 3059/4885CYP1A2 705/4885 |
| US-20110077245-A1 | SUBSTITUTED 2-ALKYL QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | ATM 81/4885NPSR1 2942/4885CYP1A2 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.